Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age

References

• Champlin R. Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol 2013;26:297-300
   PubMed Web of Science ®Google Scholar
• National coverage determination (NCD) for stem cell transplantation (110.8.1), centers for medicaid and medicare services. Available from: www.cms.gov; [Last accessed 31 January 2014]
   Google Scholar
• Rini C, Manne S, DuHamel KN, et al. Mothers’ perceptions of benefit following pediatric stem cell transplantation: a longitudinal investigation of the roles of optimism, medical risk, and sociodemographic resources. Ann Behav Med 2004;28:132-41
   PubMed Web of Science ®Google Scholar
• Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395-400
   PubMed Web of Science ®Google Scholar
• McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010;28:1878-87
   PubMed Web of Science ®Google Scholar
• Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010;28:405-11
   PubMed Web of Science ®Google Scholar
• Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011;306:1874-83
   PubMed Web of Science ®Google Scholar
• McCarthy PL Jr, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in north america, 1995-2005: Significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013;19:1116-23
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients > or = 60 years with diffuse large B-cell lymphoma: an analysis based on data in the european blood and marrow transplantation registry. Haematologica 2008;93:1837-42
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the european group for blood and marrow transplantation (EBMT). Ann Oncol 2012;23(1):166-71
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): A report from the center for international blood & marrow transplant research (CIBMTR). Biol Blood Marrow Transplant 2008;14:1323-33
   PubMedGoogle Scholar
• McClune BL, Ahn KW, Wang HL, et al. Allotransplantation for patients age ≥40 years with non-hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Costa LJ, Nista EJ, Buadi FK, et al. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification. Biol Blood Marrow Transplant 2014;20:222-8
   PubMed Web of Science ®Google Scholar
• Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 2012;53:118-122
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7
   PubMed Web of Science ®Google Scholar
• Sharma M, Zhang M, Zhong X, et al. Multiple myeloma (MM) in older (>70 year) patients - similar benefit from autologous hematopoietic cell transplantation (AHCT) compared with younger patients (Abstract). Blood 2013;122(21):416
   Google Scholar
• Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014;20(3):402-8. e1
   PubMed Web of Science ®Google Scholar
• Merz M, Neben K, Raab et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol 2014;25:189-95
   PubMed Web of Science ®Google Scholar
• Hamadani M, Craig M, Awan FT, et al. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:1259-68
   PubMedGoogle Scholar
• Muffly LS, Boulukos M, Swanson K, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant 2013;19:429-34
   PubMed Web of Science ®Google Scholar
• Social security administration, US actuarial. life tables. Available from: www.ssa.gov/OACT/STATS/table4c6.html; Last accessed 31 January 2014
   Google Scholar